FDA Approves Avapritinib for Advanced Systemic Mastocytosis

On June 16, 2021, the U.S. Food and Drug Administration (FDA) approved avapritinib for the treatment of adult patients with advanced systemic mastocytosis (SM), including aggressive SM, SM with an associated hematological neoplasm, and mast cell leukemia.

Read the FDA announcement.

Read Blueprint Medicines' announcement.

Posted 06/17/2021